Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Histone Deacetylase 6 (HDAC6) gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. It also plays a central role in microtubule-dependent cell motility via the deacetylation of tubulin.
The HDAC6 pipeline market research report provides comprehensive information on the HDAC6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
Key Therapy Areas in the HDAC6 Pipeline Products Market
The key therapy areas in the HDAC6 pipeline products market are oncology, central nervous system, genetic disorders, immunology, toxicology, respiratory, cardiovascular, gastrointestinal, infectious disease, and musculoskeletal disorders. Oncology has the highest number of pipeline products in the HDAC6 pipeline products market.
HDAC6 Pipeline Products Market Analysis by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanisms of Action in the HDAC6 Pipeline Products Market
The key mechanism of action in the HDAC6 pipeline products market is Histone Deacetylase 6 Inhibitor.
Key Routes of Administration in the HDAC6 Pipeline Products Market
The key routes of administration in the HDAC6 pipeline products market are oral, parenteral, and topical.
HDAC6 Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the HDAC6 Pipeline Products Market
The key molecule types in the HDAC6 pipeline products market are small molecule and synthetic peptide.
HDAC6 Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the HDAC6 Pipeline Products Market
Some of the major companies in the HDAC6 pipeline products market are Annji Pharmaceutical Co Ltd, ATP Biopharm, Augustine Therapeutics, Avstera Therapeutics Inc, Beijing Konruns Pharmaceutical Co Ltd, Bristol-Myers Squibb Co, Chong Kun Dang Pharmaceutical Corporation, Convalife, CStone Pharmaceuticals Co Ltd, and Curis Inc.
HDAC6 Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
HDAC6 Pipeline Products Market Report Overview
| Key Therapy Areas | Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Respiratory, Cardiovascular, Gastrointestinal, Infectious Disease, and Musculoskeletal Disorders |
| Key Mechanisms of Action | Histone Deacetylase 6 Inhibitor |
| Key Routes of Administration | Oral, Parenteral, and Topical |
| Key Molecule Type | Small Molecule and Synthetic Peptide |
| Major Companies | Annji Pharmaceutical Co Ltd, ATP Biopharm, Augustine Therapeutics, Avstera Therapeutics Inc, Beijing Konruns Pharmaceutical Co Ltd, Bristol-Myers Squibb Co, Chong Kun Dang Pharmaceutical Corporation, Convalife, CStone Pharmaceuticals Co Ltd, and Curis Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
ATP Biopharm
Augustine Therapeutics
Avstera Therapeutics Inc
Beijing Konruns Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Chong Kun Dang Pharmaceutical Corporation
Convalife
CStone Pharmaceuticals Co Ltd
Curis Inc
Eikonizo Therapeutics Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hillstream BioPharma Inc
Jubilant Therapeutics Inc
Kancera AB
Karus Therapeutics Ltd
KYAN Therapeutics Inc
Medivir AB
Merck & Co Inc
Mycovia Pharmaceuticals Inc
OnKure Inc
Oryzon Genomics SA
Quimatryx SL
Shuttle Pharmaceuticals Inc
SK Biopharmaceuticals Co Ltd
Starwise Therapeutics LLC
Suzhou GenHouse Pharmaceutical Co Ltd
Tenaya Therapeutics Inc
Table of Contents
Frequently asked questions
-
What are the key therapy areas in the HDAC6 pipeline products market?
The key therapy areas in the HDAC6 pipeline products market are oncology, central nervous system, genetic disorders, immunology, toxicology, respiratory, cardiovascular, gastrointestinal, infectious disease, and musculoskeletal disorders.
-
What are the key mechanisms of action in the HDAC6 pipeline products market?
The key mechanism of action in the HDAC6 pipeline products market is Histone Deacetylase 6 Inhibitor.
-
What are the key routes of administration in the HDAC6 pipeline products market?
The key routes of administration in the HDAC6 pipeline products market are oral, parenteral, and topical.
-
What are the key molecule types in the HDAC6 pipeline products market?
The key molecule types in the HDAC6 pipeline products market are small molecule and synthetic peptide.
-
Which are the major companies in the HDAC6 pipeline products market?
Some of the major companies in the HDAC6 pipeline products market are Annji Pharmaceutical Co Ltd, ATP Biopharm, Augustine Therapeutics, Avstera Therapeutics Inc, Beijing Konruns Pharmaceutical Co Ltd, Bristol-Myers Squibb Co, Chong Kun Dang Pharmaceutical Corporation, Convalife, CStone Pharmaceuticals Co Ltd, and Curis Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports